✦ LIBER ✦

Adjuvant lapatinib for women with early-stage HER2-positive breast cancer: a randomised, controlled, phase 3 trial

✍ Scribed by Paul E Goss; Ian E Smith; Joyce O'Shaughnessy; Bent Ejlertsen; Manfred Kaufmann; Frances Boyle; Aman U Buzdar; Pierre Fumoleau; William Gradishar; Miguel Martin; Beverly Moy; Martine Piccart-Gebhart; Kathleen I Pritchard; Deborah Lindquist; Yanin Chavarri-Guerra; Gursel Aktan; Erica Rappold; Lisa S Williams; Dianne M Finkelstein

Book ID: 119609126
Publisher: The Lancet
Year: 2013
Tongue: English
Weight: 315 KB
Volume: 14
Category: Article
ISSN: 1470-2045
DOI: 10.1016/s1470-2045(12)70508-9

No coin nor oath required. For personal study only.

📜 SIMILAR VOLUMES

Lapatinib with trastuzumab for HER2-posi

Lapatinib with trastuzumab for HER2-positive early breast cancer (NeoALTTO): a randomised, open-label, multicentre, phase 3 trial

✍ José Baselga; Ian Bradbury; Holger Eidtmann; Serena Di Cosimo; Evandro de Azambu 📂 Article 📅 2012 🏛 The Lancet 🌐 English ⚖ 320 KB

RC0639: phase II study of paclitaxel, tr

RC0639: phase II study of paclitaxel, trastuzumab, and lapatinib as adjuvant therapy for early stage HER2-positive breast cancer

✍ Alvaro Moreno-Aspitia,Amylou C. Dueck… 📂 Article 📅 2013 🏛 Springer US 🌐 English ⚖ 312 KB

Everolimus for women with trastuzumab-re

Everolimus for women with trastuzumab-resistant, HER2-positive, advanced breast cancer (BOLERO-3): a randomised, double-blind, placebo-controlled phase 3 trial

✍ André, Fabrice (author);O'Regan, Ruth (author);Ozguroglu, Mustafa (author);Toi, 📂 Article 📅 2014 🏛 Lancet Publishing Group 🌐 English ⚖ 478 KB

Everolimus for women with trastuzumab-re

Everolimus for women with trastuzumab-resistant, HER2-positive, advanced breast cancer (BOLERO-3): a randomised, double-blind, placebo-controlled phase 3 trial

✍ André, Fabrice (author);O'Regan, Ruth (author);Ozguroglu, Mustafa (author);Toi, 📂 Article 📅 2014 🏛 Lancet Publishing Group 🌐 English ⚖ 478 KB

6 months versus 12 months of adjuvant tr

6 months versus 12 months of adjuvant trastuzumab for patients with HER2-positive early breast cancer (PHARE): a randomised phase 3 trial

✍ Pivot, Xavier; Romieu, Gilles; Debled, Marc; Pierga, Jean-Yves; Kerbrat, Pierre; 📂 Article 📅 2013 🏛 The Lancet 🌐 English ⚖ 358 KB

Lapatinib with trastuzumab for HER2-posi

Lapatinib with trastuzumab for HER2-positive early breast cancer (NeoALTTO): survival outcomes of a randomised, open-label, multicentre, phase 3 trial and their association with pathological complete response

✍ De Azambuja, Evandro (author);Holmes, Andrew P. (author);Piccart-Gebhart, Martin 📂 Article 📅 2014 🏛 Lancet Publishing Group 🌐 English ⚖ 325 KB